Aberdeen Group Boosts Stake in Vaxcyte

Investment firm increases holdings in biotech company by over 35%

Apr. 5, 2026 at 7:08am

Got story updates? Submit your updates here. ›

Aberdeen Group plc, a major institutional investor, has increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 35.6% in the fourth quarter, according to a recent 13F filing with the SEC. The fund now owns nearly 980,000 shares of the clinical-stage biotech company, worth over $45 million.

Why it matters

Vaxcyte is developing a new generation of preventive vaccines targeting serious bacterial diseases, an area of significant unmet medical need. Aberdeen Group's increased investment signals confidence in the company's pipeline and future growth potential.

The details

According to the filing, Aberdeen Group acquired an additional 256,972 shares of Vaxcyte during the fourth quarter, bringing its total holdings to 979,765 shares. This represents a 0.75% ownership stake in the company. Several other institutional investors and hedge funds also added to or reduced their positions in Vaxcyte during the same period.

  • Aberdeen Group filed its 13F report for the fourth quarter on April 5, 2026.
  • The firm increased its Vaxcyte holdings during the fourth quarter of 2025.

The players

Aberdeen Group plc

A major institutional investment firm that has increased its stake in Vaxcyte, Inc.

Vaxcyte, Inc.

A clinical-stage biotechnology company focused on developing a new generation of preventive vaccines for serious bacterial diseases.

Got photos? Submit your photos here. ›

The takeaway

This investment by a major institutional player highlights the growing interest and optimism around Vaxcyte's efforts to develop innovative vaccines that could address significant unmet medical needs.